However, GW9662 cotreatment alleviated the elevated 18F-FDG uptake in the brains of LPD-treated APP/PS1 mice (P < 0.01, Fig. 3C, D). The gene discussed is APP; the disease is disseminated peritoneal leiomyomatosis.